Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies54
  • 7D-0.09%
  • 3M26.0%
  • 1Y54.4%
  • YTD-0.7%

Last week, the Pharma industry hasn't moved much but Apotex Health is up 12% in that time. The past year has been better, since the industry has gained 54% in that time. Earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Jun 2026CA$14.0bCA$10.7b-CA$1,735,065,856.358.8x-8.1x1.3x
Tue, 26 May 2026CA$15.8bCA$12.1b-CA$1,892,497,857.378.2x-8.4x1.3x
Thu, 23 Apr 2026CA$15.6bCA$11.2b-CA$1,667,280,197.0316.2x-9.4x1.4x
Sat, 21 Mar 2026CA$13.8bCA$11.2b-CA$1,694,785,958.1311.5x-8.1x1.2x
Mon, 16 Feb 2026CA$14.3bCA$11.2b-CA$1,896,001,985.4914.9x-7.5x1.3x
Wed, 14 Jan 2026CA$17.3bCA$11.3b-CA$1,957,459,682.2515.8x-8.8x1.5x
Fri, 12 Dec 2025CA$14.0bCA$11.2b-CA$1,911,460,365.6914.3x-7.3x1.2x
Sun, 09 Nov 2025CA$15.2bCA$11.3b-CA$1,868,669,889.4917.9x-8.1x1.3x
Tue, 07 Oct 2025CA$17.7bCA$11.2b-CA$2,035,782,729.1436.5x-8.7x1.6x
Thu, 04 Sep 2025CA$17.2bCA$11.2b-CA$2,025,776,747.6537.5x-8.5x1.5x
Sat, 02 Aug 2025CA$11.3bCA$11.8b-CA$2,584,257,975.7916.7x-4.4x1x
Mon, 30 Jun 2025CA$9.6bCA$11.7b-CA$2,528,266,306.6617x-3.8x0.8x
Wed, 28 May 2025CA$23.7bCA$11.8b-CA$2,399,757,618.1617.5x-9.9x2x
Fri, 25 Apr 2025CA$9.8bCA$11.9b-CA$2,536,547,725.2620.1x-3.9x0.8x
Sun, 23 Mar 2025CA$10.5bCA$12.5b-CA$2,713,893,251.5920x-3.9x0.8x
Tue, 18 Feb 2025CA$12.3bCA$12.0b-CA$2,211,294,629.2523.8x-5.5x1x
Thu, 16 Jan 2025CA$12.1bCA$12.1b-CA$2,408,322,946.1829.9x-5x1x
Sat, 14 Dec 2024CA$12.5bCA$12.0b-CA$2,588,051,717.1821.7x-4.8x1x
Mon, 11 Nov 2024CA$14.7bCA$11.9b-CA$2,626,295,288.7016.8x-5.6x1.2x
Wed, 09 Oct 2024CA$18.2bCA$11.7b-CA$2,687,034,585.1617.8x-6.8x1.6x
Fri, 06 Sep 2024CA$17.5bCA$11.6b-CA$2,693,919,323.4420.4x-6.5x1.5x
Sun, 04 Aug 2024CA$18.8bCA$11.8b-CA$3,209,781,586.6119.3x-5.9x1.6x
Tue, 02 Jul 2024CA$19.4bCA$11.8b-CA$3,241,624,247.2518.5x-6x1.6x
Thu, 30 May 2024CA$21.3bCA$11.9b-CA$3,477,631,853.2513.1x-6.1x1.8x
Sat, 27 Apr 2024CA$22.9bCA$11.8b-CA$3,444,621,037.568.4x-6.6x1.9x
Mon, 25 Mar 2024CA$24.4bCA$11.9b-CA$3,467,703,190.299.5x-7x2.1x
Wed, 21 Feb 2024CA$21.8bCA$12.0b-CA$4,651,358,851.1110.4x-4.7x1.8x
Fri, 19 Jan 2024CA$20.2bCA$12.4b-CA$6,762,355,516.009.8x-3x1.6x
Sun, 17 Dec 2023CA$17.4bCA$12.3b-CA$6,734,576,855.008.5x-2.6x1.4x
Tue, 14 Nov 2023CA$17.9bCA$12.5b-CA$6,819,154,995.008.6x-2.6x1.4x
Thu, 12 Oct 2023CA$18.1bCA$12.3b-CA$7,317,685,164.0015.4x-2.5x1.5x
Sat, 09 Sep 2023CA$20.4bCA$13.0b-CA$7,922,700,056.0015.2x-2.6x1.6x
Mon, 07 Aug 2023CA$15.2bCA$13.3b-CA$9,751,221,793.0011.9x-1.6x1.1x
Wed, 05 Jul 2023CA$15.4bCA$13.2b-CA$9,509,271,657.0012x-1.6x1.2x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$15.4bTotal Earnings: -CA$9,509,271,657.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-0.35%
Healthcare1.43%
Pharma-0.093%
Pharma-0.093%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$33.6112.0%
+CA$822.6m		n/aPE20.5x
CRON Cronos GroupCA$3.984.5%
+CA$63.5m		53.1%PS6.6x
CURA Curaleaf HoldingsCA$14.160.7%
+CA$26.4m		329.1%PS2.1x
NVRS Noveris Health SciencesCA$1.8729.0%
+CA$24.6m		648.0%PE68.3x
GUD Knight TherapeuticsCA$9.451.9%
+CA$17.7m		64.3%PE165.4x

Latest News

CURA
CA$14.16
Curaleaf Holdings
7D
0.7%
1Y
329.1%
WEED
CA$1.32
Canopy Growth
7D
-4.3%
1Y
-21.9%
OGI
CA$1.46
Organigram Global
7D
5.8%
1Y
-20.7%
Narrative Update • Jun 26

OGI: Sanity Group Acquisition Will Reshape Revenue Profile And Future Earnings Potential

Analysts have reset their fair value estimate for Organigram Global from CA$2.85 to CA$1.65. They cited updated assumptions on discount rate, revenue growth, profit margin and future P/E as the key drivers behind the new price target.
VRNO
CA$8.17
Verano Holdings
7D
2.8%
1Y
151.4%
GUD
CA$9.45
Knight Therapeutics
7D
1.9%
1Y
64.3%
Narrative Update • Jun 25

GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.
HLS
CA$4.14
HLS Therapeutics
7D
-4.6%
1Y
-13.6%
Narrative Update • Jun 23

HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance

Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
ACB
CA$4.05
Aurora Cannabis
7D
-4.0%
1Y
-29.1%
Narrative Update • Jun 23

ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus

Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.
XLY
CA$0.18
Auxly Cannabis Group
7D
-5.1%
1Y
94.7%
APTX
CA$33.61
Apotex Health
7D
12.0%
1Y
n/a
Analysis Article • Jun 20

Apotex Health (TSX:APTX) Stock Could Be 51.7% Below Fair Value After Its IPO

IPO, early trading moves and why Apotex Health is suddenly in focus Apotex Health (TSX:APTX) has quickly drawn investor attention after completing a roughly CA$1.5b IPO at CA$24 per share, with early trading marked by share price swings and debate over what the new listing is worth. The offering combined a treasury sale of new shares with a secondary sale by existing holders. This structure put fresh capital on the company’s balance sheet while giving SK Capital Partners and other...
HITI
CA$3.19
High Tide
7D
-3.9%
1Y
2.6%
VREO
CA$14.12
Vireo Growth
7D
-9.9%
1Y
-18.9%
GRIN
CA$0.57
Grown Rogue International
7D
-5.0%
1Y
9.6%
OPTI
CA$5.95
Optimi Health
7D
-16.2%
1Y
16.7%
CRON
CA$3.98
Cronos Group
7D
4.5%
1Y
53.1%
Narrative Update • Jun 14

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.
NVRS
CA$1.87
Noveris Health Sciences
7D
29.0%
1Y
648.0%
CWEB
CA$0.44
Charlotte's Web Holdings
7D
10.0%
1Y
238.5%